Perrigo Company plc $PRGO Shares Bought by CenterBook Partners LP

CenterBook Partners LP grew its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 211.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 573,644 shares of the company’s stock after buying an additional 389,492 shares during the period. CenterBook Partners LP’s holdings in Perrigo were worth $7,985,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after purchasing an additional 1,101,154 shares during the period. Dimensional Fund Advisors LP increased its position in Perrigo by 2.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock worth $171,367,000 after purchasing an additional 181,828 shares during the period. State Street Corp increased its position in Perrigo by 9.5% during the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after purchasing an additional 637,678 shares during the period. Thompson Siegel & Walmsley LLC increased its position in Perrigo by 28.4% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock worth $64,848,000 after purchasing an additional 1,029,770 shares during the period. Finally, Ion Asset Management Ltd. increased its position in Perrigo by 34.7% during the 2nd quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock worth $102,007,000 after purchasing an additional 983,727 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Up 0.1%

PRGO opened at $10.85 on Monday. The business’s fifty day moving average is $11.07 and its two-hundred day moving average is $12.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -0.83, a PEG ratio of 1.28 and a beta of 0.51. Perrigo Company plc has a one year low of $9.23 and a one year high of $28.43.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.Perrigo’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts anticipate that Perrigo Company plc will post 2.12 EPS for the current fiscal year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Friday, May 29th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 10.7%. Perrigo’s dividend payout ratio is presently -8.85%.

Analysts Set New Price Targets

Several equities analysts have issued reports on PRGO shares. Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings cut Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. Finally, Canaccord Genuity Group decreased their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.